- Home
- GLTO vs WNW Comparison
GLTO vs WNW Comparison
Compare GLTO & WNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- WNW
- Stock Information
- Founded
- GLTO 2011
- WNW 2015
- Country
- GLTO Denmark
- WNW China
- Employees
- GLTO N/A
- WNW N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- WNW Catalog/Specialty Distribution
- Sector
- GLTO Health Care
- WNW Consumer Discretionary
- Exchange
- GLTO Nasdaq
- WNW Nasdaq
- Market Cap
- GLTO 4.5M
- WNW 5.4M
- IPO Year
- GLTO 2020
- WNW 2020
- Fundamental
- Price
- GLTO $2.83
- WNW $2.20
- Analyst Decision
- GLTO Buy
- WNW
- Analyst Count
- GLTO 1
- WNW 0
- Target Price
- GLTO $10.00
- WNW N/A
- AVG Volume (30 Days)
- GLTO 248.1K
- WNW 104.2K
- Earning Date
- GLTO 10-31-2025
- WNW 11-14-2025
- Dividend Yield
- GLTO N/A
- WNW N/A
- EPS Growth
- GLTO N/A
- WNW N/A
- EPS
- GLTO N/A
- WNW 9.06
- Revenue
- GLTO N/A
- WNW $158,485.00
- Revenue This Year
- GLTO N/A
- WNW N/A
- Revenue Next Year
- GLTO N/A
- WNW N/A
- P/E Ratio
- GLTO N/A
- WNW $0.27
- Revenue Growth
- GLTO N/A
- WNW N/A
- 52 Week Low
- GLTO $2.01
- WNW $0.95
- 52 Week High
- GLTO $14.56
- WNW $70.00
- Technical
- Relative Strength Index (RSI)
- GLTO 39.82
- WNW 56.00
- Support Level
- GLTO $2.45
- WNW $1.72
- Resistance Level
- GLTO $3.99
- WNW $2.72
- Average True Range (ATR)
- GLTO 0.30
- WNW 0.35
- MACD
- GLTO -0.03
- WNW 0.06
- Stochastic Oscillator
- GLTO 24.68
- WNW 27.84
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.